An initial trial of an antibody therapy that targets Alzheimer’s disease has shown promising results and could signal a long-awaited breakthrough in treating the devastating brain disorder. In a paper published Wednesday in the journal Nature, a trial to evaluate the drug’s safety and tolerability showed positive results. If those are successful, aducanumab could be the first new Alzheimer’s drug to be approved in over a decade and the first ever to reverse signs of the disease. But for most recipients this side effect was manageable by careful monitoring and adjusting of the drug, the authors said. “This trial has reinvigorated the field and clearly created a lot more excitement about amyloid as a target,” he said of the aducanumab study.

Source: National Post September 01, 2016 13:07 UTC